0.63 ML lunsotogene parvec-cwha 30000000000000 VECTOR-GENOMES/ML Injection

RxCUI: 2741622
RxNorm name: 0.63 ML lunsotogene parvec-cwha 30000000000000 VECTOR-GENOMES/ML Injection
Display name: 0.63 ML lunsotogene parvec-cwha 30000000000000 VECTOR-GENOMES/ML Injection
Full name: 0.63 ML lunsotogene parvec-cwha 30000000000000 VECTOR-GENOMES/ML Injection
Term type: SCD
Status: DailyMed mapping
Updated: 2026-06-04 23:39:13

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
125874	OTARMENI	lunsotogene parvec-cwha	351(a)	Rx	2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
OTARMENI	LUNSOTOGENE PARVEC-CWHA	Regeneron Pharmaceuticals, Inc.	a7a5e936-ab4a-4609-ac10-96efedc89035	2026-04-27	Warnings, Adverse reactions	Exact identifier rxcui: 2741622

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
a7a5e936-ab4a-4609-ac10-96efedc89035	lunsotogene parvec-cwha 3.0 x 10(13) vg/ML in 0.63 ML Injection [PSN] · 0.63 ML lunsotogene parvec-cwha 30000000000000 VECTOR-GENOMES/ML Injection [SCD] · lunsotogene parvec-cwha 30000000000000 VECTOR-GENOMES per 0.63 ML Injection [SY]	3	4	These highlights do not include all the information needed to use OTARMENI safely and effectively. See full prescribing information for OTARMENI. OTARMENI™ (lunsotogene parvec-cwha) suspension, for intracochlear infusion Initial U.S. Approval: 2026	20260427